Merck, Inc.
🇵🇭Philippines
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 620
- Registration Number
- NCT00806585
Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)
Phase 2
Completed
- Conditions
- Carotid Atherosclerosis
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00804843
A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: MK0752
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00803894
A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)
Phase 1
Completed
- Conditions
- Tumors
- Interventions
- Other: Biomarker sample collection before and after dosing with cytotoxic agent(s)
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT00800865
A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)
Phase 1
Completed
- Conditions
- Postmenopause
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT00799708
A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)
Phase 1
Completed
- Conditions
- Mental DisordersSleep Initiation and Maintenance Disorders
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00798395
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
Phase 2
Terminated
- Conditions
- Lymphoblastic Leukemia, AcuteLeukemia, Myeloid, Acute
- Interventions
- Drug: SCH 727965Drug: Gemtuzumab ozogamicin
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 29
- Registration Number
- NCT00798213
A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 111
- Registration Number
- NCT00797745
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
Phase 2
Terminated
- Conditions
- Migraine
- Interventions
- Drug: Telcagepant 280 mgDrug: Telcagepant 140 mgDrug: 280 mg telcagepant placeboDrug: 140 mg telcagepant placebo
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 660
- Registration Number
- NCT00797667
Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)
Phase 3
Terminated
- Conditions
- Crohn's Disease
- Interventions
- Biological: InfliximabDrug: PrednisoloneDrug: AZADrug: Placebo PrednisoloneBiological: Placebo Infliximab
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT00796250
© Copyright 2025. All Rights Reserved by MedPath